|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:affiliatedWith
|
antiretroviral therapy
nucleotide analogue
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2001
|
|
gptkbp:ATCCode
|
J05AF07
|
|
gptkbp:brand
|
gptkb:tenofovir_disoproxil_fumarate
|
|
gptkbp:CASNumber
|
202138-50-9
|
|
gptkbp:chemicalFormula
|
C19H30N5O10P·C4H4O4
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:eliminationHalfLife
|
17 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Viread
|
|
gptkbp:interactsWith
|
gptkb:didanosine
gptkb:adefovir
gptkb:atazanavir
|
|
gptkbp:KEGGID
|
D08542
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:MedlinePlusID
|
a602018
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2017 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adults
children over 2 years
|
|
gptkbp:PubChem_CID
|
6398764
DB00300
CHEMBL1424
|
|
gptkbp:riskFactor
|
lactic acidosis
hepatic steatosis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
renal impairment
|
|
gptkbp:UNII
|
J3J8G2X4X4
|
|
gptkbp:usedFor
|
HIV infection
chronic hepatitis B
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:tenofovir_disoproxil_fumarate
|
|
gptkbp:bfsLayer
|
6
|